<DOC>
	<DOCNO>NCT00766545</DOCNO>
	<brief_summary>The multi-center , double-blind , placebo-controlled , randomize , group-comparison study designate assess long-term safety efficacy antiplatelet drug cilostazol prevent recurrence cerebral infarction patient suffer cerebral infarction 1 6 month prior enter trial .</brief_summary>
	<brief_title>Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial Secondary Prevention Cerebral Infarction .</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Prior cerebral infarction Onset 1 6 month randomization 2 . CT MRI detection responsible site 3 . Without serious complication ( malignant tumor , liver cirrhosis , renal failure , heart failure ) 1 . History intracranial hemorrhage 2 . Possibility cardiogenic cerebral embolism past future All patient follow complication exclude : mitral valve stenosis , prosthetic valve , endocarditis , myocardial infarction within 6 week onset , ventricular aneurysm , intraventricular intraatrial blood clot , mitral valve prolapse ( age 45 year old , lacking cause cerebral embolism induction ) , atrial fibrillation , sick sinus syndrome , idiopathic cardiomyopathy 3 . Severe cerebral deficit render patient bedridden , totally dependent , demented 4 . Contraindications study drug Hemostatic disorder systemic bleed Pregnant possibly pregnant woman , nurse mother 5 . Requirement nonstudy antiplatelet drug , anticoagulant drug , fibrinolytic drug another disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>